Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Blacks, Hispanics more concerned about Alzheimer's than whites, but less informed

Blacks and Hispanics are more concerned than whites about Alzheimer's disease but less knowledgeable about means to delay its onset, according to a new survey, United Press International reports.

5 May 2009

Episodes of delirium accelerate cognitive decline and memory loss in Alzheimer's patients

Delirium often develops in elderly patients during hospitalization or serious illness, and this acute state of confusion and agitation has long been suspected of having ties to Alzheimer's disease and other dementias.

4 May 2009

oct3 protein key to Parkinson's, drug addiction

Scientists have identified a protein that appears not only to be central to the process that causes Parkinson's disease but could also play a role in muting the high from methamphetamine and other addictive drugs.

4 May 2009

Memory becomes less efficient very early in Alzheimer's

Even very early in Alzheimer's disease, people become less efficient at separating important from less important information, a new study has found.

4 May 2009

Research uncovers possible basis of memories for different smells

Ben W. Strowbridge, Ph.D, associate professor of Neuroscience and Physiology/Biophysics, and Yuan Gao, a Ph.D. student in the neurosciences program at Case Western Reserve University School of Medicine, are the first to discover a form of synaptic memory in the olfactory bulb, the part of the brain that processes the sense of smell.

3 May 2009

Level of cellular stress determines longevity of retinal cells

Stress can be adaptive. It can make you sharper, help you focus and it can even improve your performance. But too much of it can tax cells to the point where they can no longer cope and slowly self-destruct.

30 Apr 2009

Glutamate identified as predictor of disease progression in multiple sclerosis

UCSF researchers have identified a correlation between higher levels of glutamate, which occurs naturally in the brain as a byproduct of metabolism, and greater disease burden in multiple sclerosis patients.

29 Apr 2009

SUMO protein guides chromatin remodeler to suppress genes

In an in vitro study, led by Grace Gill, PhD, Tufts University School of Medicine, researchers discovered how a protein called SUMO (Small Ubiquitin-related Modifier) guides an enzyme complex that alters the structure of chromatin to regulate expression of genes.

27 Apr 2009

Discovery of novel protein which, when over-expressed, leads to a dramatic increase in the generation of A-beta

A defining hallmark of Alzheimer's disease is the accumulation of the amyloid beta protein (A-beta), otherwise known as "senile plaques," in the brain's cortex and hippocampus, where memory consolidation occurs.

27 Apr 2009

Autoantibodies may be created in response to bacterial DNA

Autoimmune diseases have long been regarded as illnesses in which the immune system creates autoantibodies to attack the body itself. But today, researchers at the California non-profit Autoimmunity Research Foundation (ARF) explain that the antibodies observed in autoimmune disease actually result from alteration of human genes and gene products by hidden bacteria.

27 Apr 2009

Research brings new hope, old problems with Alzheimer's disease biomarkers

Brain imaging and cognitive tests may be the gold standards for tracking Alzheimer disease progression, but clinical trials using these procedures are expensive, risky, and time-consuming, making the development of reliable go-betweens a pressing goal for AD researchers.

26 Apr 2009

Breakthrough method for sequencing-based methylation profiling

Bioengineers at UC San Diego have developed a breakthrough method for sequencing-based methylation profiling, which could help fuel personalized regenerative medicine and even lead to more efficient and cost-effective methods for studying certain diseases.

23 Apr 2009

Natural plant cannabinoids reduce multi-drug resistant infections

Cannabis Science, Inc., Dr. Robert Melamede, PhD., Director and Chief Science Officer, reported to the Board on the current state of research into the use of natural plant cannabinoids to reduce the spread of drug-resistant bacteria, including methicillin-resistant Staphyloccus aureus (MRSA), and the prospects for development of topical whole-cannabis treatments.

23 Apr 2009

NSAIDs do not prevent Alzheimer's disease or other forms of dementia

A new study shows that nonsteroidal anti-inflammatory drugs (NSAIDs), such as the pain relievers ibuprofen and naproxen, do not prevent Alzheimer's disease or other forms of dementia.

22 Apr 2009

Mitochondrial peptide Humanin linked to neuronal cell survival and regulation of glucose metabolism

Recent studies have shown that the mitochondrial peptide Humanin (HN) protects against neuronal cell death such as happens in Alzheimer's disease.

22 Apr 2009

FDA gives 'go ahead' for phase II clinical trials of Bryostatin for the treatment of Alzheimer's disease

The Food and Drug Administration (FDA) has given the Blanchette Rockefeller Neurosciences Institute (BRNI) the go-ahead to conduct Phase II clinical trials of Bryostatin for the treatment of Alzheimer's disease patients.

22 Apr 2009

New applications for proton pump inhibitors

In a new study, published in the May issue of Elsevier's Experimental Neurology (www.elsevier.com/locate/yexnr), scientists at the University of British Columbia have discovered that drugs commonly used to treat ulcers have significant neuroprotective properties, which appear to be enhanced when used in combination with ibuprofen, a widely used anti-inflammatory drug.

22 Apr 2009

Discovery of agents that speed up destruction of amyloid beta proteins

Taking a new approach to the treatment and prevention of Alzheimer's disease, a research team led by investigators at the Mayo Clinic campus in Florida has shown that druglike compounds can speed up destruction of the amyloid beta (A-beta) proteins that form plaque in the brains of patients with the disorder.

22 Apr 2009

Regular exercise can prevent damage that causes leakage in the blood-brain barrier

Regular exercise can prevent the disruption of the blood brain barrier that normally occurs with a dose of methamphetamine comparable to that used by heavy meth users.

22 Apr 2009

New insights into protein p75's role Alzheimer's disease

New research at the Salk Institute for Biological Studies casts the role of a neuronal growth factor receptor - long suspected to facilitate the toxic effects of beta amyloid in Alzheimer's disease - in a new light, suggesting the molecule actually protects the neuron in the periphery from beta amyloid-induced damage.

21 Apr 2009